Moore Capital Management
DMII icon

Moore Capital Management’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Moore Capital Management’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.54M Hold
750,000
– – 0.11% 170
2026
Q1 		$7.48M Hold
750,000
– – 0.15% 115
2025
Q4 		$7.42M Buy
+750,000
New +$7.41M 0.11% 195

Other funds holding DMII

Karpus Investment Management
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Tenor Capital Management
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Moore Capital Management's DMII Position: Q2 2026 in Review

Moore Capital Management held its Drugs Made In America Acquisition II Corp (DMII) position steady in Q2 2026 at 750,000 shares worth $7.54M. The position accounts for 0.11% of the portfolio, ranked #170.

Moore Capital Management first reported a position in DMII in Q4 2025 and has held it in 3 quarters since. 69 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • Moore Capital Management held 750,000 shares of Drugs Made In America Acquisition II Corp worth $7.54M as of Q2 2026.
  • Moore Capital Management left its Drugs Made In America Acquisition II Corp share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition II Corp made up 0.11% of Moore Capital Management's portfolio in Q2 2026, its #170 holding.
  • Moore Capital Management first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 3 quarters since.
  • 69 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.